Fig. 3.
Fig. 3. Binding of uPA/suPAR-complex to piPLC pretreated vascular cells and their isolated extracellular matrix. The binding of 125I-Gly158scuPA to piPLC pretreated HVSMC (A) and HUVEC (B) (filled bars) and their respective extracellular matrix preparations (hatched bars) is compared in the absence or presence of suPAR (1 μg/mL) or MoAb-13H1 (25 μg/mL). For both cell types, data represent mean ± SEM of a typical experiment in triplicate where the maximal binding to piPLC pretreated cells in the presence of suPAR is set at 100%. Similar results were obtained in three separate experiments.

Binding of uPA/suPAR-complex to piPLC pretreated vascular cells and their isolated extracellular matrix. The binding of 125I-Gly158scuPA to piPLC pretreated HVSMC (A) and HUVEC (B) (filled bars) and their respective extracellular matrix preparations (hatched bars) is compared in the absence or presence of suPAR (1 μg/mL) or MoAb-13H1 (25 μg/mL). For both cell types, data represent mean ± SEM of a typical experiment in triplicate where the maximal binding to piPLC pretreated cells in the presence of suPAR is set at 100%. Similar results were obtained in three separate experiments.

Close Modal

or Create an Account

Close Modal
Close Modal